Forcepoint Case Studies AMAG deploys Next-Gen CASB

Edit This Case Study Record

	AMAG deploys Next-Gen CASB Forcepoint

AMAG deploys Next-Gen CASB

Forcepoint

Technology Category	Cybersecurity & Privacy - Cloud Security Infrastructure as a Service (IaaS) - Cloud Computing
Applicable Industries	Pharmaceuticals
Applicable Functions	Business Operation
Services	Cloud Planning, Design & Implementation Services Cybersecurity Services
Challenge	AMAG Pharmaceuticals, a company that develops and commercializes a therapeutic iron compound to treat iron deficiency anemia, decided to adopt G Suite as the all cloud backbone for the company. This decision was made to enhance productivity as G Suite offers a high performance productivity suite that is flexible and easy-to-use. However, combining BYOD and cloud meant that AMAG lost visibility and control of its data, risking security and compliance. Existing security solutions were not readily applicable to cloud apps and raised privacy concerns, since employees didn’t want IT monitoring their personal cloud apps or mobile devices. Read More
About Customer	AMAG Pharmaceuticals, Inc., (NASDAQ: AMAG), is a company that engages in the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The company’s principal product includes Feraheme (injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company was founded in 1981 and is headquartered in Lexington, Massachusetts. Read More
Solution	To address the challenge of data visibility and control, AMAG Pharmaceuticals deployed the Bitglass Cloud solution. This solution enables the company to transparently secure cloud and mobile usage without deploying software on premises. Bitglass monitors and controls usage of cloud apps via contextual access-control policies by user, device, and geography. With its Omni multi-protocol proxies, Bitglass is able to secure all traffic from any endpoint without complex configuration. In addition, Bitglass protects AMAG files at access with its robust cloud DLP engine. Using configurable keyword regular expression rules, AMAG can even redact sensitive content on unmanaged mobile devices. Bitglass also enables AMAG to selectively wipe corporate data from mobile devices without agents. Employees may use the native productivity clients on their personal device without the user experience hassles or privacy concerns of device management software. If a device is lost or compromised, AMAG can selectively wipe corporate data from the device and block continued access. Read More Log in to view content
Contents

Technology Category

Cybersecurity & Privacy - Cloud Security

Infrastructure as a Service (IaaS) - Cloud Computing

Applicable Industries

Pharmaceuticals

Applicable Functions

Business Operation

Services

Cloud Planning, Design & Implementation Services

Cybersecurity Services

Challenge

AMAG Pharmaceuticals, a company that develops and commercializes a therapeutic iron compound to treat iron deficiency anemia, decided to adopt G Suite as the all cloud backbone for the company. This decision was made to enhance productivity as G Suite offers a high performance productivity suite that is flexible and easy-to-use. However, combining BYOD and cloud meant that AMAG lost visibility and control of its data, risking security and compliance. Existing security solutions were not readily applicable to cloud apps and raised privacy concerns, since employees didn’t want IT monitoring their personal cloud apps or mobile devices.

About Customer

AMAG Pharmaceuticals, Inc., (NASDAQ: AMAG), is a company that engages in the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia (IDA). The company’s principal product includes Feraheme (injection for intravenous (IV) use, which was approved for marketing in the United States in June 2009 by the U.S. Food and Drug Administration, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease (CKD). The company was founded in 1981 and is headquartered in Lexington, Massachusetts.

Solution

To address the challenge of data visibility and control, AMAG Pharmaceuticals deployed the Bitglass Cloud solution. This solution enables the company to transparently secure cloud and mobile usage without deploying software on premises. Bitglass monitors and controls usage of cloud apps via contextual access-control policies by user, device, and geography. With its Omni multi-protocol proxies, Bitglass is able to secure all traffic from any endpoint without complex configuration. In addition, Bitglass protects AMAG files at access with its robust cloud DLP engine. Using configurable keyword regular expression rules, AMAG can even redact sensitive content on unmanaged mobile devices. Bitglass also enables AMAG to selectively wipe corporate data from mobile devices without agents. Employees may use the native productivity clients on their personal device without the user experience hassles or privacy concerns of device management software. If a device is lost or compromised, AMAG can selectively wipe corporate data from the device and block continued access.

Impact #1	Enhanced productivity through the use of G Suite.
Impact #2	Improved data visibility and control with the Bitglass Cloud solution.
Impact #3	Secured all traffic from any endpoint without complex configuration.

Impact #1

Enhanced productivity through the use of G Suite.

Impact #2

Improved data visibility and control with the Bitglass Cloud solution.

Impact #3

Secured all traffic from any endpoint without complex configuration.

Download PDF Version

Overview

AMAG deploys Next-Gen CASB

Operational Impact